Analysts Split on AbbVie Inc. (ABBV) as BofA Cuts Target and HSBC Turns Bullish

We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. 

TheFly reported on December 15 that Bank of America (BofA) lowered its price target for ABBV to $233 from $248 while maintaining a Neutral rating, reflecting a modestly reduced valuation outlook even as the company’s core business fundamentals remain solid.

On December 10, HSBC also raised its rating on ABBV from Hold to Buy and increased its price target to $265, signaling greater confidence in ABBV’s growth prospects.

The divergent analyst perspectives relate in part to AbbVie Inc. (NYSE:ABBV)’s ongoing transition away from Humira toward newer immunology products Skyrizi and Rinvoq. These drugs have been strong revenue drivers in 2025. According to recent reporting, Skyrizi and Rinvoq together generated about $18.5 billion in sales in the first nine months of 2025.

AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company that discovers, develops, manufactures, and sells a diverse portfolio of advanced therapies. It is a major player in the immunology, oncology, neuroscience, and aesthetics markets.

While we acknowledge the risk and potential of ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Best Blue Chip Stocks to Buy Under $50 and11 Best Low Priced Dividend Stocks to Buy According to Analysts.

Disclosure: None.